Rituximab inhibits B-cell receptor signaling

Blood

Volumn 115, Issue 5, 2010, Pages 985-994

  Kheirallah, Samar ^a,b   Caron, Pierre ^a,b   Gross, Emilie ^a,b   Quillet Mary, Anne ^a,b   Bertrand Michel, Justine ^a   Fournié, Jean Jacques ^a,b   Laurent, Guy ^a,b,c   Bezombes, Christine ^b  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CALCIUM; CHOLESTEROL; IMMUNOGLOBULIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C GAMMA2; PROTEIN KINASE B; PROTEIN KINASE LYN; PROTEIN KINASE SYK; RITUXIMAB; LYMPHOCYTE ANTIGEN RECEPTOR; LYN PROTEIN-TYROSINE KINASE; MONOCLONAL ANTIBODY; PHOSPHOLIPASE C GAMMA; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; PTPN6 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ARTICLE; CALCIUM MOBILIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LIPID RAFT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; TIME; CELL CULTURE; CELL MEMBRANE; FLOW CYTOMETRY; GENETICS; METABOLISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CALCIUM; CELL LINE, TUMOR; CELLS, CULTURED; CHOLESTEROL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE MICRODOMAINS; PHOSPHOLIPASE C GAMMA; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANTIGEN, B-CELL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TIME FACTORS;

EID: 77649196743     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-237537     Document Type: Article

References (48)

1. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med. 2008;59:237-250.
2. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9(1):10-25.
3. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359-7368.
4. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008;20(4):444-449.
5. Bonavida B. Rituximab-induced inhibition of anti-apoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic inter-ventions. Oncogene. 2007;26(25):3629- 3636.
6. Janas E, Priest R, Wilde JI, White JH, Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol. 2005;139(3):439-446.
7. Bezombes C, Grazide S, Garret C, et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood. 2004;104(4):1166-1173.
8. Semac I, Palomba C, Kulangara K, et al. Anti -CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res. 2003;63(2):534-540.
9. Leseux L, Laurent G, Laurent C, et al. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood. 2008;111(1):285-291.
10. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001;7(3):709-723.
11. Jazirehi AR, Gan XH, De Vos S, Emmanouilides C, Bonavida B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2003;2(11):1183-1193.
12. Reth M. Antigen receptor tail clue. Nature. 1989;338(6214):383-384.
13. Tolar P, Sohn HW, Pierce SK. Viewing the antigen-induced initiation of B cell activation in living cells. Immunol Rev. 2008;221:64-76.
14. Pierce SK. Lipid rafts and B cell activation. Nat Rev Immunol. 2002;2(2):96-105.
15. Gupta N, DeFranco AL. Lipid rafts and B cell signaling. Semin Cell Dev Biol. 2007;18(5):616-626.
16. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol. 2004;41(6):599-613.
17. Keshvara LM, Isaacson CC, Yankee TM, Sarac R, Harrison ML, Geahlen RL. Syk- and Lyn-dependent phosphorylation of Syk on multiple tyrosines following B cell activation includes a site that negatively regulates signaling. J Immunol. 1998;161(10):5276-5283.
18. Campbell KS. Signal transduction from the B cell antigen-receptor. Curr Opin Immunol. 1999;11(3):256-264.
19. Reth M, Brummer T. Feedback regulation of lymphocyte signaling. Nat Rev Immunol. 2004;4(4):269-277.
20. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B cell receptor signaling is a rational treatment target in diffuse large B cell lymphoma. Blood. 2008;111(4):2230-2237.
21. Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood. 2006;108(9):3135-3142.
22. Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 2004;23(20):3530-3540.
23. Macdonald JL, Pike LJ. A simplified method for the preparation of detergent-free lipid rafts. J Lipid Res. 2005;46(5):1061-1067.
24. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
25. Siakotos AN, Rouser G, Fleischer S. Phospholipid composition of human, bovine and frog myelin isolated on a large scale from brain and spinal cord. Lipids. 1969;4(3):239-242.
26. Cheng PC, Dykstra ML, Mitchell RN, Pierce SK. A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J Exp Med. 1999;190(11):1549-1560.
27. Cheng PC, Brown BK, Song W, Pierce SK. Translocation of the B cell antigen receptor into lipid rafts reveals a novel step in signaling. J Immunol. 2001;166(6):3693-3701.
28. Blery M, Tze L, Miosge LA, Jun JE, Goodnow CC. Essential role of membrane cholesterol in accelerated BCR internalization and uncoupling from NF-kappa B in B cell clonal anergy. J Exp Med. 2006;203(7):1773-1783.
29. Karnell FG, Brezski RJ, King LB, Silverman MA, Monroe JG. Membrane cholesterol content accounts for developmental differences in surface B cell receptor compartmentalization and signaling. J Biol Chem. 2005;280(27):25621- 25628.
30. Bourget I, Breittmayer JP, Grenier-Brossette N, Cousin JL. CD20 monoclonal antibodies down-regulate IgM at the surface of B cells. Eur J Immunol. 1993;23(3):768-771.
31. Ho SC, Chaudhuri S, Bachhawat A, McDonald K, Pillai S. Accelerated proteasomal degradation of membrane Ig heavy chains. J Immunol. 2000;164(9):4713-4719.
32. Elkabetz Y, Kerem A, Tencer L, Winitz D, Kopito RR, Bar-Nun S. Immunoglobulin light chains dictate vesicular transport-dependent and -independent routes for IgM degradation by the ubiquitinproteasome pathway. J Biol Chem. 2003;278(21):18922-18929.
33. Hayslip J, Montero A. Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Mol Cancer. 2006;5:44.
34. Radcliffe CM, Arnold JN, Suter DM, et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B cell receptor. J Biol Chem. 2007;282(10):7405-7415.
35. Walewski J, Kraszewska E, Mioduszewska O, et al. Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. Med Oncol. 2001;18(2):141-148.
36. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100(6):2257-2259.
37. Jenks SA, Sanz I. Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev. 2009;8(3):209-213.
38. Leseux L, Hamdi SM, Al Saati T, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood. 2006;108(13):4156-4162.
39. Young RM, Hardy IR, Clarke RL, et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood. 2009;113(11):2508-2516.
40. Friedberg JW, Sharman J, Schaefer-Cutillo J, et al. Fostamatinib disodium (FosD), an oral inhibitor of Syk, is well-tolerated and has significant clinical activity in diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (SLL/CLL). Blood (ASH Annual Meeting Abstracts). 2008;112:3.
41. Petrie RJ, Deans JP. Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J Immunol. 2002;169(6):2886-2891.
42. Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers physically associate with the B cell antigen receptor: dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem. 2008;283(27):18545-18552.
43. Walshe CA, Beers SA, French RR, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem. 2008;283(25):16971-16984.
44. Hochstenbach F, David V, Watkins S, Brenner MB. Endoplasmic reticulum resident protein of 90 kilodaltons associates with the T- and B cell antigen receptors and major histocompatibility complex antigens during their assembly. Proc Natl Acad Sci U S A. 1992;89(10):4734-4738.
45. Foy SP, Matsuuchi L. Association of B lymphocyte antigen receptor polypeptides with multiple chaperone proteins. Immunol Lett. 2001;78(3):149-160.
46. Dylke J, Lopes J, Dang-Lawson M, Machtaler S, Matsuuchi L. Role of the extracellular and transmembrane domain of Ig-alpha/beta in assembly of the B cell antigen receptor (BCR). Immunol Lett. 2007;112(1):47-57.
47. London M, London E. Ceramide selectively displaces cholesterol from ordered lipid domains (rafts): implications for lipid raft structure and function. J Biol Chem. 2004;279(11):9997-10004.
48. Subbaiah PV, Sowa JM, Singh DK. Sphingolipids and cellular cholesterol homeostasis: effect of ceramide on cholesterol trafficking and HMG CoA reductase activity. Arch Biochem Biophys. 2008;474(1):32-38.